Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Fineline Cube Apr 17, 2026
Company Deals

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Fineline Cube Apr 17, 2026
Company Deals

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Fineline Cube Apr 17, 2026
Company Deals Digital

Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials

Fineline Cube Apr 17, 2026
Company Deals

Amoytop Biotech Inks $445M Deal with Aligos for China Rights to Novel Hepatitis B Capsid Modulator Pevifoscorvir

Fineline Cube Apr 17, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

Sunshine Lake Pharma Secures NMPA Approval for In-House Developed Premixed Insulin 30R Prefilled Pen

Fineline Cube Apr 17, 2026
Company Drug

Hansoh Pharma’s B7-H3 ADC HS-20093 Secures Fourth NMPA Breakthrough Therapy Designation for NSCLC Combination Therapy

Fineline Cube Apr 17, 2026
Drug Policy / Regulatory

Azvudine Included in China’s COVID-19 Treatment Protocol

Fineline Cube Oct 12, 2022

The National Healthcare Commission and the National Administration of Traditional Chinese Medicine have released a...

Company Drug

NMPA Approves IND Filing for Henan Genuine Biotech’s Long-Acting HIV Drug CL-197

Fineline Cube Oct 12, 2022

China-based Henan Genuine Biotech Co., Ltd’s investigational new drug (IND) filing for its oral long-acting...

Company Deals

WuXi Biologics Partners with Toregem BioPharma on Anti-USAG-1 Monoclonal Antibody

Fineline Cube Oct 12, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...

Company Deals

BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development

Fineline Cube Oct 12, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership...

Company Medical Device

NMPA Approves Beijing Union Strong’s Intracranial Aneurysm Surgical Planning Software

Fineline Cube Oct 12, 2022

The National Medical Products Administration (NMPA) has approved the marketing of Beijing Union Strong Technology...

Company Deals

Aier Eye Hospital Group Plans IPO on ChiNext Board

Fineline Cube Oct 12, 2022

China-based ophthalmic medical services provider Aier Eye Hospital Group Co., Ltd (SHE: 300015) is set...

Company Deals

BeiGene Partners with Immune-Onc for Clinical Development of Myeloid Checkpoint Inhibitors

Fineline Cube Oct 12, 2022

China-based biotech BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a clinical study...

Company Deals

Cyagen Biosciences Partners with Neurophth for Ophthalmology AAV Capsid Development

Fineline Cube Oct 12, 2022

Cyagen Biosciences, a provider of custom-engineered mouse and rat models with operations in the US...

Company Deals

IASO Biotherapeutics Licenses CD19 Binder to Cabaletta Bio for Autoimmune Diseases

Fineline Cube Oct 12, 2022

China-based IASO Biotherapeutics has announced a licensing agreement with US firm Cabaletta Bio Inc. (NASDAQ:...

Company Drug

Henlius Biotech’s HanBeiTai Biosimilar Accepted for Review by CDE

Fineline Cube Oct 12, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...

Hospital Policy / Regulatory

Shanghai Launches High-Quality Development Pilot for Public Hospitals

Fineline Cube Oct 12, 2022

The Shanghai Municipal Health Commission (SHC) has released a notification regarding the public hospital high-quality...

Drug Policy / Regulatory

NMPA Introduces Electronic Certificates for Biologics and Narcotic Drugs

Fineline Cube Oct 12, 2022

The National Medical Products Administration (NMPA) has released a notification regarding the initiation of electronic...

Policy / Regulatory

CDE Releases Draft Guidelines for Tumor Therapeutic Vaccine Clinical Trials

Fineline Cube Oct 12, 2022

The Center for Drug Evaluation (CDE) has released the “Tumor Therapeutic Vaccines Clinical Trial Technical...

Company Deals

SprintRay Raises Over USD 100M in Series D Financing for Dental 3D Printing

Fineline Cube Oct 12, 2022

Zhejiang-based SprintRay Co., a one-stop digital chair side solution provider for dental institutions, has reportedly...

Company Drug

Pfizer’s Zavicefta Approved in China for Pediatric Complex Intra-Abdominal Infections

Fineline Cube Oct 11, 2022

US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced that it has received market approval from...

Company Drug

HutchMed Initiates Phase II/III Study of Sovleplenib for Warm AIHA

Fineline Cube Oct 11, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initiation of a...

Company Deals

Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China

Fineline Cube Oct 11, 2022

Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...

Company Drug

Guangdong Zhongsheng Receives USPTO Patent for FGFR4 Inhibitor ZSP1241

Fineline Cube Oct 11, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced receiving a patent award from...

Company Drug

Simcere Completes Enrollment for Phase III Study of CDK4/6 Inhibitor in mTNBC

Fineline Cube Oct 11, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of first-line enrollment for its...

Company Drug

Hengrui Medicine’s Pyrotinib Filing Accepted for Review by NMPA

Fineline Cube Oct 11, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its supplementary market filing...

Posts pagination

1 … 603 604 605 … 653

Recent updates

  • AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products
  • Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform
  • Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu
  • Sunshine Lake Pharma Secures NMPA Approval for In-House Developed Premixed Insulin 30R Prefilled Pen
  • Hansoh Pharma’s B7-H3 ADC HS-20093 Secures Fourth NMPA Breakthrough Therapy Designation for NSCLC Combination Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Company Deals

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Company Deals

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Company Drug

Sunshine Lake Pharma Secures NMPA Approval for In-House Developed Premixed Insulin 30R Prefilled Pen

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.